Early use of intensive disease-modifying therapy (DMT) represents a paradigm shift in the management of multiple sclerosis (MS), and has prompted researchers to rethink treatment goals, according to a presenter at a ECTRIMS 2022.
The treatment of MS has evolved rapidly, noted Dr Gavin Giovannoni of Queen Mary University of London, UK, in a Hot Topic session at the conference. Treatment strategies have also evolved from a conventional step-wise increase in therapy as disease activity increases to rapid escalation of DMT, particularly for patients at higher risk.